DXCM logo

DexCom Inc. (DXCM)

$66.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on DXCM

Market cap

$26.12B

EPS

1.79

P/E ratio

38.5

Price to sales

5.95

Dividend yield

--

Beta

1.514502

Price on DXCM

Previous close

$68.94

Today's open

$69.03

Day's range

$66.68 - $69.31

52 week range

$54.11 - $93.25

Profile about DXCM

CEO

Jake Leach

Employees

10300

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

390016272

Issue type

Common Stock

DXCM industries and sectors

Healthcare

Medical Equipment & Supplies

News on DXCM

DXCM DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 29 Deadline in Securities Class Action – DXCM

NEW YORK, Dec. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”) of the important December 29, 2025 lead plaintiff deadline.

news source

GlobeNewsWire • 17 hours ago

news preview

Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.

news source

GlobeNewsWire • Dec 12, 2025

news preview

DexCom, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of those who purchased or otherwise acquired DexCom securities between July 26, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses,.

news source

Business Wire • Dec 12, 2025

news preview

Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS)

ATLANTA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits:

news source

GlobeNewsWire • Dec 12, 2025

news preview

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 26, 2025.

news source

GlobeNewsWire • Dec 11, 2025

news preview

DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights – DXCM

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).

news source

GlobeNewsWire • Dec 11, 2025

news preview

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 26, 2025 in DexCom, Inc. Lawsuit - DXCM

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

news source

PRNewsWire • Dec 11, 2025

news preview

DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DXCM

LOS ANGELES , Dec. 11, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  DexCom, Inc. ("DexCom " or "the Company") (NASDAQ: DXCM ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

news source

PRNewsWire • Dec 11, 2025

news preview

High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth

The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to size was a relative tailwind to performance, offsetting a headwind from being underweight volatility. Consumer Discretionary was the largest source of relative gains.

news source

Seeking Alpha • Dec 11, 2025

news preview

DXCM Deadline: DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit

NEW YORK , Dec. 10, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline. So what: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

news source

PRNewsWire • Dec 10, 2025

news preview

¹ Disclosures

Get started with M1

Invest in DexCom Inc.

Open an M1 investment account to buy and sell DexCom Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in DXCM on M1